drugset / Trial / NCT01359787

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

NCT01359787

Phase 2 Completed 197 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to ointment base (vehicle) in subjects with Atopic Dermatitis (AD).

Timeline

Start
2011-05
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mapracorat Small molecule 0.01 % Topical
Comparator Mapracorat Small molecule 0.03 % Topical
Comparator Mapracorat Small molecule 0.1 % Topical

Indications